Handelsbanken Fonder’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Handelsbanken Fonder’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,000	Closed	-$395K	–	1600
2020 Q4	$395K	Buy	+3,000	New	+$265K	﹤0.01%	1281

Handelsbanken Fonder's EIDX Position: Q1 2021 in Review

Handelsbanken Fonder sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 3,000 shares — an estimated $395K sold.

Handelsbanken Fonder first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $395K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Handelsbanken Fonder reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Handelsbanken Fonder sold 3,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $395K.
Handelsbanken Fonder first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Handelsbanken Fonder's Eidos Therapeutics, Inc. Common Stock position peaked at $395K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Handelsbanken Fonder's 13F filing for Q1 2021, filed 29 Apr 2021.